Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Romyelocel-L + filgrastim
- Development stage
- Unknown
- Lead developer
- Cellerant Therapeutics
- Modality
- Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Romyelocel-L + filgrastim is a combination therapy comprising **Romyelocel-L**, an allogeneic myeloid progenitor cell product, and **filgrastim**, a recombinant human granulocyte colony-stimulating factor (G-CSF) analog. This combination is designed to reduce morbidity and mortality from infections during neutropenia following myeloablative chemotherapy, specifically in patients with acute myeloid leukemia (AML)[7]. Romyelocel-L provides a source of functional myeloid cells, while filgrastim stimulates the proliferation and differentiation of neutrophil precursors in the bone marrow through activation of the G-CSF receptor[1][4][6][7]. The strategy is intended to accelerate hematopoietic recovery and reduce infectious complications associated with post-chemotherapy neutropenia.
- Other names
- Romyelocel-L + G-CSF
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on Romyelocel-L + filgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Romyelocel-L + filgrastim.